A new drug combination from Corcept Therapeutics, relacorilant, has shown potential in treating platinum-resistant ovarian cancer.
A phase 3 trial found that relacorilant, when combined with chemotherapy drug nab-paclitaxel, improved progression free survival compared to the chemotherapy alone, according to a March 31 news release from the drugmaker.
Patients receiving relacorilant had a 30% lower risk of disease progression, with a median progression free survival of 6.5 months compared to 5.5 months for those on chemotherapy alone.
Corcept Therapeutics plans to submit a new drug application with the FDA in the third quarter of 2025, with full trial results expected to be presented at a medical conference later this year.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
